Indo-U.S. Vaccine Action Program (VAP) Initiative on Tuberculosis (TB) Research: Regional Prospective Observational Research for Tuberculosis- RePORT India RFP
CRDF Global is accepting proposals on behalf of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH), and the Government of India’s (GOI) Department of Biotechnology, (DBT)) to fund a single network of multiple clinical research sites addressing an array of TB biomedical and clinical research of importance to India and abroad. Funding for this research award initiative will be jointly administered by CRDF Global, and the Government of India’s Department of Biotechnology and Indian Council of Medical Research, using funds from the National Institutes of Health and the Government of India.
Currently, India accounts for about a quarter of the global TB burden and has the highest burden of both TB and MDR TB of any country.“Global TB Report 2017”, WHO, 2017 There are an estimated 79,000 multi-drug resistant TB patients among the notified cases of pulmonary TB each year. India is also the country with the second highest number of estimated HIV associated TB cases (https://www.tbfacts.org/). The development of drugs, vaccines and diagnostics for TB is urgently needed to bring the epidemic to an end, and research to achieve these aims is critical. The study of TB patients and their contacts in a longitudinal cohort will increase fundamental understanding of both TB disease and infection and will provide the basis for the development of new tools that can facilitate the rapid end to the TB epidemic, especially in high risk populations such as people living with HIV and those with diabetes mellitus.
Please find application's electronic proposal submission (EPS) site here once made available on Wednesday, December 12th:
UPDATE: The RFP has been amended to clarify Allowable Costs under Section VII and to clarify page count limit for Project Narrative